A5059940608- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Chronic Lymphocytic Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Hemoglobinopathies and Related Disorders
- Neonatal Respiratory Health Research
- Cytomegalovirus and herpesvirus research
- Viral-associated cancers and disorders
- Antifungal resistance and susceptibility
- Immunodeficiency and Autoimmune Disorders
- Prenatal Screening and Diagnostics
- Lysosomal Storage Disorders Research
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Fungal Infections and Studies
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
- Parvovirus B19 Infection Studies
- Complement system in diseases
- Radiation Therapy and Dosimetry
- Polyomavirus and related diseases
- Oral health in cancer treatment
- Pericarditis and Cardiac Tamponade
University of California, San Francisco
2019-2025
UCSF Benioff Children's Hospital
2019-2025
Stanford University
2011-2021
Lok Nayak Jai Prakash Narayan Hospital
2019
Lucile Packard Children's Hospital
2011-2017
Lurie Children's Hospital
2017
University of Alabama at Birmingham
2008
Masonic Cancer Center
2006
University of Minnesota
2004-2006
Children's Hospital of Pittsburgh
2002
Significance Through massive shotgun sequencing of circulating cell-free DNA from the blood more than 1,000 independent samples, we identified hundreds new bacteria and viruses which represent previously unidentified members human microbiome. Previous studies targeted specific niches such as feces, skin, or oral cavity, whereas our approach using effectively enables sampling entire body reveals colonization have been inaccessible. We were thus able to discover that contains a vast unexpected...
Reduced-intensity conditioning (RIC) regimens have the potential to decrease toxicities related hematopoietic stem cell transplantation (HCT) in patients with sickle disease (SCD) and thus make HCT a more acceptable therapeutic option for this group of patients. We report results 7 enrolled on study evaluate safety efficacy using bone marrow from an HLA matched sibling donor following RIC regimen high-risk SCD. The consisted busulfan, fludarabine, equine antithymocyte globulin, total...
Quantification of cell-free DNA (cfDNA) in circulating blood derived from a transplanted organ is powerful approach to monitoring post-transplant injury. Genome transplant dynamics (GTD) quantifies donor-derived cfDNA (dd-cfDNA) by taking advantage single-nucleotide polymorphisms (SNPs) distributed across the genome discriminate donor and recipient molecules. In its current implementation, GTD requires genotyping both donor. However, practice, genotype information often unavailable. Here, we...
Allogeneic hematopoietic stem cell transplantation for patients with a hemoglobinopathy can be curative but is limited by donor availability. Although positive results are frequently observed in those an HLA-matched sibling donor, use of unrelated donors has been complicated poor engraftment, excessive regimen-related toxicity, and graft-versus-host disease (GVHD). As potential strategy to address these obstacles, pilot study was designed that incorporated both reduced-intensity conditioning...
Abstract Background Transplant‐associated thrombotic microangiopathy (TA‐TMA) is an endothelial injury complication of hematopoietic stem cell transplant (HSCT) leading to end‐organ damage and high morbidity mortality. Defibrotide anti‐inflammatory antithrombotic agent that may protect the endothelium during conditioning. Procedure We hypothesized prophylactic use defibrotide HSCT conditioning acute recovery could prevent TA‐TMA. A pilot single‐arm phase II trial (NCT#03384693) evaluated...
Successful allogeneic hematopoietic cell transplantation (HCT) for genetic non-malignant diseases (NMD) is dependent upon elimination of host stem cells (HSCs) and replacement with donor HSCs in stable numbers sufficient to correct the underlying disease. Donor myeloid chimerism (DMC) peripheral blood (PB) a surrogate marker bone marrow HSC engraftment due rapid turnover PB cells. Busulfan commonly used during conditioning patients NMD, though its optimal exposure avoid inadequate DMC not...
Dose assessment after radiological disasters is imperative to decrease mortality through rationally directed medical intervention. Our goal was identify biomarkers capable of qualitative (nonirradiated/irradiated) and/or quantitative (dose) radiation exposure. Using real-time PCR, biodosimetry genes were identified in blood samples from cancer patients undergoing total-body irradiation. Time- (5, 12, 23, 48 h) and dose- (0–8 Gy) dependent changes gene expression examined C57BL/6 mice. A...
Population pharmacokinetic (PK) studies demonstrate model-based dosing for busulfan that incorporates body size and age improve clinical target attainment as compared to weight-based regimens. Recently, of TDM, our institution transitioned a cloud-based decision support tool (www.insight-rx.com). The goal this study was assess the dose achievement exposure in children undergoing hematopoietic cell transplantation (HCT).Patients (N = 188) were grouped into cohorts A, B, or C based on method...
Total body irradiation (TBI)-based conditioning is the standard of care in treatment acute lymphoblastic leukemia (ALL) that requires allogeneic hematopoietic stem cell transplantation (HSCT). However, TBI known to be associated with an increased risk late effects, and therefore, non-TBI regimens have also been utilized successfully. A recent study showed patients were next-generation sequencing-minimal residual disease (NGS-MRD) negative prior HSCT had a very low relapse, perhaps could...
Transplant-associated thrombotic microangiopathy (TA-TMA) is an endothelial injury syndrome that complicates hematopoietic stem cell transplant (HSCT). Morbidity and mortality from TA-TMA remain high, making prevention critical. We describe our retrospective single-center experience of after pediatric allogeneic HSCT present a novel pre-HSCT risk-stratification system prophylaxis regimen. From January 2012 through October 2019, 257 patients underwent 292 HSCTs. Prospective risk...
Patients with inherited metabolic storage disorders are at a higher risk of developing pulmonary complications after hematopoietic cell transplantation (HCT). This single-center prospective study 48 consecutive disorder patients was performed to identify factors for the development HCT. Before HCT, subjects underwent bronchoalveolar lavage (BAL) count, culture, nitrite levels, and analysis proinflammatory cytokines chemokines. The overall incidence 52% (infectious, 23%; noninfectious, 29%)...
Allogeneic hematopoietic cell transplantation (HCT) is curative in patients with β-thalassemia major. However, most reports on HCT outcomes lack long-term follow-up data the exception of single-center reports. An international multicenter retrospective collection and analysis was conducted 176 who were 1 year or beyond after first to evaluate methods at 7 centers. Median age 5.5 years (range, .6 18.5), median 20). predominantly from HLA-matched related donors (91%) bone marrow as stem source...